Invasive Pulmonary Aspergillosis in a Puerperant with Drug-induced Agranulocytosis.

  • AOKI Fumiaki
    the Department of Medicine, Social Insurance Gunma Chuo General Hospital
  • SANDO Yoshichika
    the Second Department of Internal Medicine, Gunma University, School of Medicine
  • TAJIMA Syunji
    the Department of Medicine, Social Insurance Gunma Chuo General Hospital
  • IMAI Kunihiko
    the Department of Medicine, Social Insurance Gunma Chuo General Hospital
  • HOSONO Tatsuya
    the Second Department of Internal Medicine, Gunma University, School of Medicine
  • MAENO Toshitaka
    the Second Department of Internal Medicine, Gunma University, School of Medicine
  • SUGA Tatsuo
    the Second Department of Internal Medicine, Gunma University, School of Medicine
  • SUGANO Jinpei
    the Department of Medicine, Social Insurance Gunma Chuo General Hospital
  • SHITARA Yoshinori
    the First Department of Surgery, Gunma University, School of Medicine
  • KURABAYASHI Masahiko
    the Second Department of Internal Medicine, Gunma University, School of Medicine

この論文をさがす

抄録

Invasive pulmonary aspergillosis (IPA) is an acute infection of Aspergillus species to the lungs. It generally occurs in immunocompromised hosts, especially with neutropenia. We report a 30-year-old puerperant, who developed IPA from agranulocytosis. She had been treated for threatened labor with ritodrine and cefepime, one of which induced agranulocytosis. After vaginal delivery of twins, pneumonia emerged in the right lower lobe. She was diagnosed to have IPA according to the halo sign on computed tomography (CT) and positive circulating antibody against Aspergillus, and was treated successfully with oral itraconazole followed by surgical resection. It is important to note that IPA might arise in otherwise immunocompetent hosts when neutropenia is long-standing.<br>(Internal Medicine 40:1128-1131, 2001)

収録刊行物

  • Internal Medicine

    Internal Medicine 40 (11), 1128-1131, 2001

    一般社団法人 日本内科学会

被引用文献 (2)*注記

もっと見る

参考文献 (17)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ